Methods for inhibiting the activity of the P40 subunit of human IL-12
View Patent ↗Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
1. A method for inhibiting the activity of the p40 subunit of IL-12 in a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a K d of 1×10 −10 M or less or a k off rate constant of 1×10 −3 s −1 or less, as determined by surface plasmon resonance, thereby inhibiting the activity of the p40 subunit of IL-12 in said subject.
2. The method of claim 1 , wherein the autoimmune disorder is psoriasis.
3. The method of claim 1 , wherein the autoimmune disorder is rheumatoid arthritis.
4. The method of claim 1 , wherein the autoimmune disorder is Crohn's disease.
5. The method of claim 1 , wherein the autoimmune disorder is Multiple Sclerosis.
6. The method of claim 1 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12.
7. The method of claim 1 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to a p19 subunit.
8. The method of claim 1 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12 and when the p40 subunit is bound to a p19 subunit.
9. The method of claim 1 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit of IL-12 to which an antibody selected from the group consisting of Y61 and J695 binds.
10. The method of claim 1 , wherein the antibody is further capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of Il-12 and the p35 subunit of Il-12, and wherein the second heterodimer comprises the p40 subunit of IL-12 and a p19 subunit.
11. The method of claim 10 , wherein the antibody neutralizes the biological activity of the first heterodimer.
12. The method of claim 10 , wherein the antibody neutralizes the biological activity of the second heterodimer.
13. The method of claim 10 , wherein the antibody neutralizes the biological activity of the first heterodimer and the second heterodimer.
14. The method of claim 10 , wherein the antibody, or antigen binding portion thereof, inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −9 M or less, or which inhibits human IFNγ production with an IC 50 of 1×10 −10 M or less.
15. The method of claim 1 , wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a K d of 9.74 ×10 −11 M or less or a k off rate constant of 1×10 −4 s −1 or less, as determined by surface plasmon resonance.
16. The method of claim 1 , wherein the antibody, or antigen binding portion thereof, has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29 and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.
17. A method for inhibiting the activity of an interleukin comprising a p40 subunit in a human subject suffering from an autoimmune disorder, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an interleukin comprising a p40 subunit, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of the interleukin with a K d of 1×10 −10 M or less or a k off rate constant of 1×10 −3 s −1 or less, as determined by surface plasmon resonance, thereby inhibiting the activity of an interleukin comprising a p40 subunit in said subject.
18. The method of claim 17 , wherein the autoimmune disorder is psoriasis.
19. The method of claim 17 , wherein the autoimmune disorder is rheumatoid arthritis.
20. The method of claim 17 , wherein the autoimmune disorder is Crohn's disease.
21. The method of claim 17 , wherein the autoimmune disorder is Multiple Sclerosis.
22. The method of claim 17 , wherein the interleukin comprises a p40 subunit and a p35 subunit.
23. The method of claim 22 , wherein the interleukin is IL-12.
24. The method of claim 17 , wherein the interleukin comprises a p40 subunit and a p19 subunit.
25. The method of claim 17 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit.
26. The method of claim 17 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit to which an antibody selected from the group consisting of Y61 and J695 binds.
27. The method of claim 17 , wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of the interleukin with a K d of 9.74×10 −11 M or less or a k off rate constant of 1×10 4 s −1 or less, as determined by surface plasmon resonance.
28. The method of claim 17 , wherein the antibody, or antigen binding portion thereof, neutralizes the biological activity of the interleukin.
29. The method of claim 28 , wherein the antibody, or antigen binding portion thereof, inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −9 M or less, or which inhibits human IFNγ production with an IC 50 of 1×10 −10 M or less.
30. The method of claim 17 , wherein the antibody, or antigen binding portion thereof, has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29 and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.
31. A method for inhibiting the activity of the p40 subunit of IL-12 in a human subject suffering from psoriasis, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a K d of 1×10 −10 M or less or a k off rate constant of 1×10 −3 s −1 or less, as determined by surface plasmon resonance, thereby inhibiting the activity of the p40 subunit of IL-12 in the subject.
32. The method of claim 31 , wherein the subject exhibits an improvement in skin condition for an extended period following administration of the antibody, or antigen-binding portion thereof.
33. The method of claim 32 , wherein the subject exhibits flattening of plaques.
34. The method of claim 32 , wherein the subject exhibits a decrease in scaling.
35. The method of claim 31 , wherein the subject exhibits a total clearance of plaques for an extended period following administration of the antibody, or antigen-binding portion thereof.
36. The method of claim 31 , wherein said effective amount is about 0.01 mg/kg to about 10 mg/kg.
37. The method of claim 31 , wherein said antibody, or antigen-binding portion thereof, is administered to said subject subcutaneously.
38. The method of claim 31 , wherein said antibody, or antigen-binding portion thereof, is administered to said subject intravenously.
39. The method of claim 31 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12.
40. The method of claim 31 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to a p19 subunit.
41. The method of claim 31 , wherein the antibody, or antigen-binding portion thereof, is capable of binding to the epitope of the p40 subunit when the p40 subunit is bound to the p35 subunit of IL-12 and when the p40 subunit is bound to a p19 subunit.
42. The method of claim 31 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit of IL-12 to which an antibody selected from the group consisting of Y61 and J695 binds.
43. The method of claim 31 , wherein the antibody is further capable of binding to a first heterodimer and is also capable of binding to a second heterodimer, wherein the first heterodimer comprises the p40 subunit of Il-12 and the p35 subunit of Il-12, and wherein the second heterodimer comprises the p40 subunit of IL-12 and a p19 subunit.
44. The method of claim 43 , wherein the antibody neutralizes the biological activity of the first heterodimer.
45. The method of claim 43 , wherein the antibody neutralizes the biological activity of the second heterodimer.
46. The method of claim 43 , wherein the antibody neutralizes the biological activity of the first heterodimer and the second heterodimer.
47. The method of claim 43 , wherein the antibody, or antigen binding portion thereof, inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −9 M or less, or which inhibits human IFNγ production with an IC 50 of 1×10 −10 M or less.
48. The method of claim 31 , wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of IL-12 with a K d of 9.74 ×10 −11 M or less or a k off rate constant of 1×10 −4 s −1 or less, as determined by surface plasmon resonance.
49. The method of claim 31 , wherein the antibody or antigen binding portion thereof, has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29 and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.
50. A method for inhibiting the activity of an interleukin comprising a p40 subunit in a human subject suffering from psoriasis, comprising administering to the human subject an effective amount of a human antibody, or antigen-binding portion thereof, which is capable of binding to an interleukin comprising a p40 subunit, wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of the interleukin with a K d of 1×10 −10 M or less or a k off rate constant of 1×10 −3 s −1 or less, as determined by surface plasmon resonance, such that the psoriasis is treated.
51. The method of claim 50 , wherein the subject exhibits an improvement in skin condition for an extended period following administration of the antibody, or antigen-binding portion thereof.
52. The method of claim 51 , wherein the subject exhibits flattening of plaques.
53. The method of claim 51 , wherein the subject exhibits a decrease in scaling.
54. The method of claim 50 , wherein the subject exhibits a total clearance of plaques for an extended period following administration of the antibody, or antigen-binding portion thereof.
55. The method of claim 50 , wherein said effective amount is about 0.01 mg/kg to about 10 mg/kg.
56. The method of claim 50 , wherein said antibody, or antigen-binding portion thereof, is administered to said subject subcutaneously.
57. The method of claim 50 , wherein said antibody, or antigen-binding portion thereof, is administered to said subject intravenously.
58. The method of claim 50 , wherein the interleukin comprises a p40 subunit and a p35 subunit.
59. The method of claim 58 , wherein the interleukin is IL-12.
60. The method of claim 50 , wherein the interleukin comprises a p40 subunit and a p19 subunit.
61. The method of claim 50 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit.
62. The method of claim 50 , wherein the antibody, or antigen binding portion thereof, binds to an epitope of the p40 subunit to which an antibody selected from the group consisting of Y61 and J695 binds.
63. The method of claim 50 , wherein the antibody, or antigen binding portion thereof, dissociates from the p40 subunit of the interleukin with a K d of 9.74×10 −11 M or less or a k off rate constant of 1×10 31 4 s −1 or less, as determined by surface plasmon resonance.
64. The method of claim 50 , wherein the antibody, or antigen binding portion thereof, neutralizes the biological activity of the interleukin.
65. The method of claim 64 , wherein the antibody, or antigen binding portion thereof, inhibits phytohemagglutinin blast proliferation in an in vitro PHA assay with an IC 50 of 1×10 −9 M or less, or which inhibits human IFNγ production with an IC 50 of 1×10 −10 M or less.
66. The method of claim 50 , wherein the antibody, or antigen binding portion thereof, has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27 and a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29 and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30.